Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Harvard Business School
McKinsey
Express Scripts
Johnson and Johnson

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD7594

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug AZD7594?

AZD7594 is an investigational drug.

There have been 10 clinical trials for AZD7594. The most recent clinical trial was a Phase 2 trial, which was initiated on October 12th 2018.

The most common disease conditions in clinical trials are Lung Diseases, Pulmonary Disease, Chronic Obstructive, and Lung Diseases, Obstructive. The leading clinical trial sponsors are AstraZeneca, Parexel, and Quotient Sciences.

There are eight US patents protecting this investigational drug and one hundred and forty-six international patents.

Recent Clinical Trials for AZD7594
TitleSponsorPhase
A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.ParexelPhase 1
A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.AstraZenecaPhase 1
A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With AsthmaParexelPhase 1

See all AZD7594 clinical trials

Clinical Trial Summary for AZD7594

Top disease conditions for AZD7594
Top clinical trial sponsors for AZD7594

See all AZD7594 clinical trials

US Patents for AZD7594

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD7594   Start Trial Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE)   Start Trial
AZD7594   Start Trial Phenyl and benzodioxinyl substituted indazoles derivatives AstraZeneca AB (Sodertalje, SE) Bayer Schering Pharma AG (Berlin, DE)   Start Trial
AZD7594   Start Trial Phenyl and benzodioxinyl substituted indazoles derivatives Astrazeneca AB (Sodertalje, SE) Bayer Pharma Aktiengesellschaft (Berlin, DE)   Start Trial
AZD7594   Start Trial Phenyl and benzodioxinyl substituted indazoles derivatives AstraZeneca AB (Sodertalje, SE) Bayer Pharma Aktiengesellschaft (Berlin, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD7594

Drugname Country Document Number Estimated Expiration Related US Patent
AZD7594 Argentina 099177 2034-01-24   Start Trial
AZD7594 Australia 2015208932 2034-01-24   Start Trial
AZD7594 Australia 2017200338 2034-01-24   Start Trial
AZD7594 Australia 2018202956 2034-01-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKesson
Baxter
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.